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The pentavalent Tc-99m dimercaptosuccinic acid (Tc-
99m (V) DMSA, Tc(V)-DMSA) radiotracer has become
more widely used. The accumulation of Tc(V)-DMSA
in tumors was first reported in 1981 [1], and this
tracer has subsequently been shown to localize in a
variety of tumors [2,3]. Tc(V)-DMSA has also been
used to depict abscesses and other inflammatory
lesions [4–6]. Compared with conventional inflam-
mation and the tumor-imaging agent Ga-67 citrate
(Ga-citrate), Tc(V)-DMSA has superior characteristics,
such as better physical properties, lower cost, and less
time delay between radiotracer injection and imag-
ing. In addition, compared with some recently devel-
oped radiopharmaceuticals for oncologic imaging, such
as monoclonal antibodies, metabolic substrates and
receptor-avid peptides, Tc(V)-DMSA remains cost-
effective, widely available and clinically accepted.
Despite years of experience with Tc(V)-DMSA
imaging, the precise mechanism by which Tc(V)-DMSA
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As a critical step toward elucidating the mechanism of localization of Tc-99m (V) dimercaptosuccinic
acid (DMSA), we investigated its binding and transport in blood in comparison with Ga-67 
citrate. The studies were performed in vitro by incubating Tc-99m (V) DMSA with blood (one
sample at 4°C and another at 37°C) to assess its binding to plasma proteins using ultrafiltration,
dialysis, electrophoresis, gel filtration chromatography and affinity chromatography. A parallel
experiment for determining the blood binding of Ga-67 citrate was performed using the same
procedures. Using ultrafiltration, dialysis, electrophoresis and gel filtration chromatography,
labeled plasma samples showed that protein binding for Tc-99m (V) DMSA was 45–54% at 
37°C and 73–80% at 4°C. The figures for Ga-67 citrate were 43–53% at 37°C and 75–81% at 
4°C. Electrophoresis showed that Tc-99m (V) DMSA was mostly bound to plasma albumin
(36.05 ± 2.48% at 37°C and 60.04 ± 1.87% at 4°C), and that the proportion of Ga-67 radioactivity
associated with β-globulin was 34.23 ± 1.37% at 37°C and 55.71 ± 3.69% at 4°C. In affinity chro-
matography experiments, Tc-99m (V) DMSA did not bind to transferrin, unlike Ga-67 citrate.
This study demonstrates that, at the radiopharmaceutical tracer level, most Tc-99m (V) DMSA
in blood is protein-bound, primarily to albumin, but not to transferrin. In contrast, Ga-67 
citrate was bound primarily to transferrin. The knowledge that albumin is the main transport
protein of Tc-99m (V) DMSA may contribute to a better understanding of its biodistribution and
pharmacokinetics.
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accumulates remains controversial. The chemical iden-
tity of Tc(V)-DMSA was determined using analytical
methods [7]. It has been suggested the tumor affinity
of Tc(V)-DMSA can be attributed to the structural sim-
ilarity of the TcO4−3 core to the PO4−3 ion [8]. A pH-
dependent mechanism has also been advanced, based
on evidence of increased accumulation of Tc(V)-DMSA
in tumor cells with acidification both in vitro and
in vivo [9,10]. In addition, Tc(V)-DMSA has an affinity
for calcified materials [11]. Watkinson et al [12]
showed that Tc(V)-DMSA has a bioexponential blood
clearance, but did not mention blood binding or
transport. Furthermore, Tc(V)-DMSA enters cancer-
cell-line models, specifically via the type III NaPi co-
transporter (PiTl) [13]. PiTl activity is inhibited
during the early stages of apoptosis, leading to dif-
ferential incorporation of Tc(V)-DMSA in viable cells
and apoptotic cells, both in vitro and in vivo [14]. Yet,
to the best of our knowledge, there are no published
studies on the specific binding of Tc(V)-DMSA to 
specific classes of proteins.
The interaction of different drugs with circulatory
proteins is of great importance because this influ-
ences both their distribution in the body and the rate
of their elimination. Therefore, we aimed to study the
interactions of Tc(V)-DMSA with blood, to ascertain
which plasma proteins transported Tc(V)-DMSA, and
to determine what influences the biodistribution of
Tc(V)-DMSA. We hypothesized this information might
lead to improved imaging and therapeutic results,
since the pharmacokinetic properties of Tc(V)-DMSA
and Re-186 (V) DMSA are similar [15].
There are similarities and differences between the
clinical imaging diagnosis of Tc(V)-DMSA and Ga-
citrate. Both Tc(V)-DMSA and Ga-citrate images
showed abnormal uptake in some tumors [2,3] and
inflammatory lesions [4–6]. However, Tc(V)-DMSA
scans are positive and Ga-citrate scans are negative in
schwannomas [2] and mediastinal neurilemmomas [3].
Several investigators have reported that serum trans-
ferrin transports Ga-citrate to tumor tissues [16–18].
Transferrin receptors on tumor cells may be involved
in tumor accumulation [17]. Moreover, hypotheses
for the tumor uptake of Ga-67 include endocytosis of
protein-bound gallium by tumor cells, diffusion across
hyperpermeable tumor cells and plasma membranes,
and exchange of transferrin-bound gallium with lac-
toferrin. We investigated whether Tc(V)-DMSA and
Ga-citrate manifested similar or different biological
properties in terms of blood binding and transport.
The specific nature of Tc(V)-DMSA binding to partic-
ular plasma proteins has not yet been established.
To understand the mechanism of localization of
Tc(V)-DMSA in specific target tissues, the interactions
of Tc(V)-DMSA with plasma proteins are important.
We examined two aspects of the interactions of Tc(V)-
DMSA: total protein binding and the specificity of
binding to certain classes of proteins. Using the same
procedures, we also studied the binding of Ga-citrate
to plasma proteins for comparison and to validate the
experimental procedures by checking their agreement
with previous reports [16–18].
MATERIALS AND METHODS
Preparing radiopharmaceuticals
Tc(V)-DMSA was prepared by adding 370 MBq of
sodium pertechnetate Tc-99m into a commercially
available Tc(V)-DMSA kit (INER DMS Kit; INER,
Taoyuan, Taiwan) containing 1.0 mg of DMSA, 5.0 mg
of sodium bicarbonate, 9.0 mg of sodium chloride,
1.0 mg of ascorbic acid and 0.5 mg of stannous chloride
per vial. The radiochemical purity of the Tc(V)-DMSA
was checked using instant thin-layer chromatography.
Labeling purity was > 95% for each preparation. The
radiotracer Ga-citrate was obtained from the Radio-
chemical Center (DuPont, Billerica, MA, USA).
Radioactivity in blood cells and plasma
Between August 2000 and July 2002, 36 healthy vol-
unteers (18 men, 18 women; weight range, 60–85 kg;
age range, 45–60 years) were fasted for about 11 hours.
Eight-milliliter blood samples were drawn from the
left forearm vein into lithium-heparinized vacutainers.
We took triplicate 2-mL samples from each whole-
blood sample and added 370 kBq of Tc(V)-DMSA.
After 2 hours of incubation (one sample at 4°C and
another at 37°C), the labeled samples were centri-
fuged at 3,500 rpm for 10 minutes at room temperature
(approximately 25°C). The radioactivities of packed
blood cells and supernatant were measured with a
gamma counter (COBRA II; Packard, Meriden, CT,
USA). The relative distribution of radioactivity between
the packed cells and the plasma was determined. As
a comparison, Ga-citrate was identically analyzed.
The remaining labeled plasma from each whole-
blood sample was tested to determine total protein
binding as well as the relative distribution of Tc(V)-
DMSA among the major protein fractions. Due to
logistical limitations, not all tests could be performed
on all labeled plasma samples. The same procedures
were performed for Ga-67. All tests were performed
twice to confirm the reproducibility of the results.
Total protein binding: ultrafiltration
A 0.2-mL sample of labeled plasma was placed 
in a membrane ultrafiltration cone (Amicon Corp.,
Lexington, MA, USA) for retention of molecules above
25,000 Da. The cones were centrifuged at 3,000 rpm
for 15 minutes and centrifuged again after adding
0.2 mL of water (pH 7.5), following which the radioac-
tivities of filtrates and residues were measured using
a gamma counter. Total protein binding was calcu-
lated as a percentage of the radioactivity in the applied
plasma sample retained in the cone. As a control, a
similar procedure was followed for Tc(V)-DMSA alone,
and the percentage of radioactivity bound to the cone
was determined.
Total protein binding: dialysis
A 1-mL labeled plasma sample was dialyzed at 4°C
for 24 hours in physiological saline (pH 7.4), using 
a dialysis membrane that retained molecules above
12,000 Da. After dialysis, the contents of the dialysis
bag and the dialyzed fluid were taken and counted
using a gamma counter. Total protein binding was
calculated as a percentage of the applied plasma radio-
activity retained inside the membrane. As a control,
Tc(V)-DMSA alone samples were dialyzed in the same
manner.
Total protein binding: gel filtration
chromatography
A 1.5 × 30-cm gel column (Sephadex G-50; Pharmacia
Fine Chemicals, Inc., Piscataway, NJ, USA) was pre-
pared and equilibrated with a 0.05-M sodium bicar-
bonate buffer (pH 7.5). Transferrin (1 mg) was passed
through the column as a routine precaution to block
any protein binding sites on the gel. A 0.1-mL sample
of labeled plasma was applied to the column and
eluted with the bicarbonate buffer. Column eluates
were consecutively collected and radioactivities meas-
ured using a gamma counter. As a control, the elution
patterns of Tc(V)-DMSA alone were determined. Total
protein binding was calculated as a percentage of the
applied radioactivity that appeared in the protein
region in the void volume. The total radioactivity recov-
ered from the column, expressed as a percentage of
the applied radioactivity, was also determined.
Distribution among plasma proteins:
agarose gel electrophoresis
We used agarose gel electrophoresis to separate and
quantify plasma proteins. Labeled plasma samples
(3µL) were placed onto an agarose plate and allowed to
diffuse into the agarose for 4 minutes. Electrophoresis
was run at 120 volts for 15 minutes in TITAN GEL
Plasma Protein Buffer (Helena Laboratories, Beaumont,
TX, USA). As a control, the electrophoretic behavior
of Tc(V)-DMSA alone was determined. At the end of
each run, the electrophoretograms were stained with
amido black and destained in 7% acetic acid. The five
protein bands (albumin, and alpha1 (α1), alpha2 (α2),
beta (β) and gamma (γ) globulins) observed following
gel electrophoresis were individually cut out and their
radioactivities measured, along with any radioactiv-
ity that had migrated beyond the albumin band,
using a gamma counter. The relative distribution 
of Tc(V)-DMSA in the applied plasma sample was
calculated as a percentage of the radioactivity that
appeared in each electrophoretic fraction. The total
radioactivity recovered on the agarose plate, expressed
as a percentage of the applied radioactivity, was also
determined.
Specific transferrin binding: affinity
chromatography
The IgG fraction of sheep anti-human transferrin
(4.3 mg) (Serotec, Raleigh, NC, USA) was incubated
with cyanogen-bromide-activated Sepharose 4B (1 g)
(Pharmacia) for 2 hours in a coupling buffer (0.1 M
sodium bicarbonate plus 0.5 M sodium chloride; pH
8.3). Unbound antibody was removed by washing
the gel with the coupling buffer, after which the
unoccupied binding sites on the Sepharose gel were
inactivated by incubating it overnight with 1-M glycine
(pH 8.5). The gel was then washed with the coupling
buffer (pH 8.3) and, finally, with alternate portions 
of 0.1-M acetate buffer (pH 4.0) and 0.1-M borate
buffer (pH 8.0). Columns with 2-mL bed volumes
were prepared from disposable 3-mL plastic syringes.
A 0.05-mL labeled plasma sample was applied to the
column, incubated with the gel for 15 minutes, and
then eluted with normal saline (pH 8.0) in 1-mL incre-
ments until no further radioactivity appeared in the
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eluate. As a control, Tc(V)-DMSA alone samples were
applied to the column, incubated, and eluted in the
same fashion. Binding to transferrin was calculated
as a percentage of the applied radioactivity retained
on the column. The efficiency of transferrin retention
by the column was determined to be 98% using I-125
transferrin. To dissociate the antigen–antibody com-
plex and recover the radioactivity retained by the 
gel, the column was thoroughly washed with 3 M of
guanidine hydrochloride (pH 2.0).
Statistical analysis
Values are expressed as mean ± standard deviation
(SD). Statistical comparisons were performed using
Student’s t test with a significance level of 0.05.
RESULTS
Radioactivity in blood cells and 
plasma
After human whole blood samples with Tc(V)-DMSA
or Ga-citrate had been incubated for 2 hours, the rela-
tive distribution of radioactivity in blood cells and
plasma was similar for both radiotracers, and both
showed statistically significant (p < 0.05) differences
between the levels in blood cells and plasma at 37°C
and 4°C (Table 1).
Total protein binding: ultrafiltration 
and dialysis
Ultrafiltration and dialysis experiments indicated
that 60–75% of the Tc(V)-DMSA and Ga-citrate was
protein-bound (Table 2). In contrast, little radioactiv-
ity was retained in the membrane ultrafiltration cone
or the dialysis membrane after Tc(V)-DMSA alone or
Ga-citrate alone had been separately analyzed (data
not shown).
Total protein binding: gel filtration
chromatography
On the elution profile obtained using Sephadex G-50
filtration, Tc(V)-DMSA alone samples showed a sin-
gle distinct peak, well resolved from the protein
peaks in the void volumes at 37°C (Figure A) and 4°C
(data not shown). Ga-citrate alone samples at 37°C
(Figure B) and 4°C (data not shown) showed similar
results. The levels of protein binding were calculated
to be 54.12 ± 3.21% at 37°C and 73.24 ± 2.82% at 4°C
for Tc(V)-DMSA plasma samples, and 52.96 ± 1.89%
at 37°C and 70.18 ± 2.11% at 4°C for Ga-citrate plasma
samples.
Distribution among plasma proteins:
agarose gel electrophoresis
The characteristic plasma protein fractionation pattern
obtained using agarose gel electrophoresis included
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Table 1. Relative distribution of radioactivity in blood cells and plasma*
Blood cells Plasma
37°C 4°C 37°C 4°C
Agent
Tc(V)-DMSA 22.17 ± 1.47† 15.67 ± 1.63† 78.83 ± 1.72† 82.83 ± 1.47†
Ga-citrate 20.83 ± 0.75† 17.50 ± 1.87† 79.33 ± 2.16† 83.17 ± 2.32†
*Data are expressed as % ± standard deviation, n = 6; †p < 0.05 between 37°C and 4°C (Student’s t test).
Table 2. Tc(V)-DMSA and Ga-citrate bound to plasma proteins: based on ultrafiltration and dialysis*
Ultrafiltration Dialysis
37°C 4°C 37°C 4°C
Agent
Tc(V)-DMSA 52.83 ± 2.86† 79.83 ± 1.47† 44.50 ± 1.64† 77.67 ± 1.51†
Ga-citrate 52.17 ± 2.64† 60.04 ± 1.87† 43.50 ± 2.43† 74.67 ± 1.63†
*Data are expressed as % ± standard deviation, n = 6; †p < 0.05 between 37°C and 4°C (Student’s t test).
five bands representing albumin and the α1, α2, β and
γ globulins (Table 3). Radioactivity with greater mobil-
ity than albumin was considered to be unbound
Tc(V)-DMSA. The proportion of bound Tc(V)-DMSA
radioactivity associated with the albumin fraction
was 36.05 ± 2.48% at 37°C and 60.04 ± 1.87% at 4°C;
for the other four fractions, the proportions bound
ranged between 2% and 3% (Table 3). The proportion
of Ga-citrate radioactivity associated with the β band
was 34.23 ± 1.37% at 37°C and 55.71 ± 3.69% at 4°C;
for the other four fractions, the proportions bound
ranged between 4% and 6%. These results revealed
that Tc(V)-DMSA bound primarily to plasma albu-
min and that Ga-citrate bound primarily to plasma 
β globulin.
Specific transferrin binding: affinity
chromatography
In the affinity chromatography experiment, 87.50 ±
1.87% at 37°C and 95.50 ± 1.87% at 4°C of the applied
Ga-citrate plasma radioactivity was retained by the
column and, thus, was bound to transferrin. When
Tc-99m (V) DMSA binding to human plasma proteins
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Figure. (A) A representative example of a Sephadex G-50 gel filtration chromatogram of a Tc-99m (V) DMSA plasma sample (dotted
line) and the elution pattern of a Tc-99m (V) DMSA alone sample (solid line), both at 37°C. Protein binding was calculated to be 
54.12 ± 3.21% at 37°C and 73.24 ± 2.82% at 4°C. (B) A representative example of a Sephadex G-50 gel filtration chromatogram of a
Ga-citrate plasma sample (dotted line) and the elution pattern of a Ga-citrate alone sample (solid line), both at 37°C. Protein binding
was calculated to be 52.96 ± 1.89% at 37°C and 70.18 ± 2.11% at 4°C.
Ga-67 alone, Tc(V)-DMSA plasma and Tc(V)-DMSA
alone samples were applied to the affinity column,
the retained radioactivity ranged between 1% and 2%
at both 37°C and 4°C.
Temperature significantly affects 
plasma protein binding
Our results showed that there was a significant
(p < 0.05) difference in the levels of plasma protein
binding at 37°C and 4°C (Tables 2–4), suggesting that
temperature significantly affects the plasma protein
binding of these two radiopharmaceuticals.
DISCUSSION
The interaction of a radiopharmaceutical with plasma
proteins is an important characteristic influencing
both its biodistribution over the whole body and its
pharmacokinetics. In this study, we explored and
compared the blood binding and transport of Tc(V)-
DMSA and Ga-citrate because both radiotracers can
be used to image tumors and inflammation. We found
that these two radiotracers have similar and different
properties.
In whole blood, both Tc(V)-DMSA and Ga-citrate
were distributed primarily in the plasma and had a
high degree of plasma protein binding. In addition,
both radiotracers showed a significant difference 
in plasma protein binding between 37°C and 4°C,
which corroborated the finding of Tsan et al [18] that
the percentage of Ga-67 binding to plasma proteins
was temperature dependent. This temperature effect
is most likely due to a combination of increased dis-
sociation of Ga-67 from Ga-67–plasma protein com-
plexes and increased diffusion of Ga-67 at 37°C [18].
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Table 4. Affinity chromatography: percentage of Tc(V)-
DMSA and Ga-citrate bound to transferrin*
Bound to transferrin
37°C 4°C
Sample type
Tc(V)-DMSA plasma 1.67 ± 0.82 1.83 ± 1.17
Tc(V)-DMSA alone 1.50 ± 0.84 1.50 ± 0.55
Ga-citrate plasma 87.50 ± 1.87† 95.50 ± 1.87†
Ga-citrate alone 1.83 ± 0.75 1.67 ± 0.52
*Data are expressed as % ± standard deviation, n = 6; †p < 0.05
between 37°C and 4°C (Student’s t test).
A similar conclusion can be drawn about the temper-
ature effect of Tc(V)-DMSA–plasma protein binding.
An interesting finding of the present study was
that different protein groups have distinctly different
affinities for binding Tc(V)-DMSA and Ga-citrate:
Tc(V)-DMSA bound mostly to the albumin fractions,
while Ga-citrate bound mostly to β-globulins. Electro-
phoresis at 37°C showed greater dissociations of these
two protein-bound radiopharmaceuticals compared
with those at 4°C.
Our finding that albumin is the main transport
protein of Tc(V)-DMSA may contribute to a better
understanding of the biodistribution and pharmaco-
kinetics of this radiotracer. Binding of Tc(V)-DMSA to
albumin contrasts with the negligible albumin binding
of the renal imaging agent Tc-99m DMSA (III-DMSA).
III-DMSA binds preferably to α and β globulin frac-
tions. This kind of bound form permits III-DMSA
to reach specific target tissues, such as the kidneys,
where it accumulates [19].
Maiorino et al [20] observed that DMSA, a thera-
peutically effective chelating agent for treating lead
intoxication, was bound by disulfide linkage mostly
to albumin in the plasma. Plasma proteins appear to
serve as a depot and reservoir for DMSA. Some other
radiopharmaceuticals bind with albumin, such as the
tumor-imaging agent Tc-99m-DL-homocysteine [21].
Tc(V)-DMSA had a bi-exponential blood clearance and
cumulative urine excretion in New Zealand white
rabbits [12]. Wang et al [22] demonstrated the 18-kDa
peptide expressed on tumor cells is a principal plasma
albumin-binding protein (ABP). Albumin is the most
abundant protein in plasma, present at 50 g/L, and
has a half-life of 19 days in humans. Plasma albumin
was found to bind specifically with the correspon-
ding ABP, which is believed to play a significant role
in transcytosis. Our results showed that albumin
serves as a carrier for the transport of Tc(V)-DMSA,
which may decrease the elimination of this radio-
tracer into urine, maintain its blood concentration,
and subsequently cause it to accumulate in tumor
cells or inflamed tissue. Further study is needed to
investigate the mechanism of Tc(V)-DMSA release
from Tc(V)-DMSA-albumin complexes and its uptake
by tumor cells or inflamed tissue. Whether such a
binding-releasing interaction between Tc(V)-DMSA
and plasma albumin is a significant factor in its accu-
mulation in tumor cells or inflamed tissue remains to
be elucidated.
The present study, as well as other studies [16–18],
demonstrated that the main plasma protein binding
Ga-citrate is transferrin. It is transported to normal,
inflamed or tumorous tissues predominantly in Ga-
67–transferrin complexes. The entry of Ga-citrate into
tumor tissue involves simple diffusion of the unbound
or loosely bound form of Ga-citrate, whereas its uptake
is strongly promoted by its binding to transferrin.
Moreover, Ga-citrate localization in tumors involves
endocytosis of Ga-67–transferrin receptor complexes
via the transferrin receptor [17].
Both Tc(V)-DMSA and Ga-citrate, which are used
to image inflammation and some tumors, bind pri-
marily to plasma proteins. The major carrier of Tc(V)-
DMSA is albumin and that of Ga-citrate is transferrin.
These different binding proteins may affect their
biodistribution and pharmacokinetics.
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